Skip to main content
Veracyte, Inc. (VCYT)
NASDAQ: VCYT · Real-Time Price · USD
39.44
+0.24 (0.60%)
Nov 21, 2024, 11:09 AM EST - Market open

Veracyte Revenue

Veracyte had revenue of $115.86M in the quarter ending September 30, 2024, with 28.58% growth. This brings the company's revenue in the last twelve months to $425.33M, up 23.95% year-over-year. In the year 2023, Veracyte had annual revenue of $361.05M with 21.76% growth.

Revenue (ttm)
$425.33M
Revenue Growth
+23.95%
P/S Ratio
6.95
Revenue / Employee
$521,879
Employees
815
Market Cap
3.06B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2023361.05M64.52M21.76%
Dec 31, 2022296.54M77.02M35.09%
Dec 31, 2021219.51M102.03M86.85%
Dec 31, 2020117.48M-2.89M-2.40%
Dec 31, 2019120.37M28.36M30.82%
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro
Dec 31, 2014 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Surgery Partners 2.99B
LivaNova 1.24B
ACADIA Pharmaceuticals 929.24M
Warby Parker 742.53M
HUTCHMED (China) 610.81M
Amicus Therapeutics 493.67M
Kymera Therapeutics 87.56M
Verona Pharma 5.62M
Revenue Rankings

VCYT News

More News